Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards

Salarius Pharmaceuticals (SLRX) received a conditional extension from Nasdaq to regain compliance with listing requirements, specifically the minimum stockholders' equity ($2.5 million) by early July 2025 and minimum bid price ($1.00/share) by early August 2025. Failure to meet these milestones could result in delisting, stemming from prior non-compliance with both equity and bid price rules, including a Delisting Notice received on April 23, 2025. SLRX is currently trading at $1.08, up 71.3% following the announcement.

Analysis

Salarius Pharmaceuticals, Inc. (SLRX) has secured a conditional extension from The Nasdaq Stock Market LLC, providing a critical window to rectify its non-compliance with continued listing requirements concerning minimum stockholders' equity and minimum bid price. The Nasdaq Hearings Panel has mandated that Salarius achieve a minimum stockholders' equity of $2.5 million by early July 2025 and restore compliance with the $1.00 per share minimum bid price rule by early August 2025. This development follows significant regulatory pressure, including a Delisting Notice received on April 23, 2025, for its stock trading below $1.00 for 30 consecutive business days, and a notification on March 26, 2025, regarding its failure to meet the Equity Standard, as detailed in its 2024 fiscal year-end Form 10-K. Notably, due to a reverse stock split within the prior 12 months, Salarius was ineligible for the standard 180-day grace period for the bid price issue, and Nasdaq did not accept its remediation plan due to concurrent non-compliance with both rules, leading to the Hearings Panel review. The market has responded with significant optimism to the extension, evidenced by SLRX shares surging 71.3% to $1.08, thereby temporarily meeting the bid price requirement; however, failure to meet the specified conditions within the given timeframes could lead to delisting from the Nasdaq Capital Market.

Key Decisions for Investors

• Investors should recognize that while the Nasdaq extension offers Salarius a crucial opportunity, substantial risk remains tied to achieving the $2.5 million stockholders' equity by early July 2025 and consistently maintaining the $1.00 minimum bid price by early August 2025.
• Diligently track Salarius's forthcoming financial reports and any announced strategic actions, such as capital raising or operational improvements, aimed at bolstering its equity position and sustaining its stock price above the required Nasdaq threshold.
• Be mindful of the inherent volatility and binary nature of this situation; the pronounced stock surge to $1.08 reflects immediate market relief, but sustained compliance with Nasdaq's conditions is paramount to avoid the significant risk of delisting.